Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting — Sponsor Intelligence | 50 EU Trials

Filter these 50 trials by condition, phase, country and more.

Open in Search →

50 Registered trials

29 Recruiting

15 Completed trials

12 Countries active

84 Unique IMPs

100% Results reported

Phase III

Phase II/III

Phase II

Phase III: 8 Phase II/III: 6 Phase II: 22 Phase I/II: 4 Phase IV: 4 Phase I: 1 Phase I (Other): 4 Phase I (FiH): 1

Oversight events:

5 serious breaches 1 temporary halt 2 corrective measures across 6 trials

View oversight register →

100%

15 of 15 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Colorectal cancer metastatic 2 HER2 positive breast cancer 2 Triple negative breast cancer 1 Breast cancer metastatic 1 EGFR gene mutation 1 Prostate cancer 1 Colorectal cancer 1 Pleural mesothelioma malignant recurrent 1 Clear cell renal cell carcinoma 1

Top IMPs

NIVOLUMAB 10 IPILIMUMAB 8 ATEZOLIZUMAB 5 PEMBROLIZUMAB 5 CAPECITABINE 4 PACLITAXEL 4 BEVACIZUMAB 3 CARBOPLATIN 3 CISPLATIN 3 OLAPARIB 3 OXALIPLATIN 3 3-(4-METHYLPIPERAZINE-1-CARBONYL)-7-OXABICLO[2.2.1]HEPTANE-2-CARBOXYLIC ACID 2

All trials — page 2

50 total

Phase I/II study with galunisertib combined with capecitabine in patients with advanced chemotherapy resistant colorectal cancer with perito… Recruiting

2024-518980-37-00 Phase I/II 1 country CAPECITABINE; GALUNISERTIB
FIGO 2018 stage IB2 (>2 cm - ≤4 cm ) Cervical Cancer Treated with Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery (CoNteSSa)… Recruiting

2023-507230-24-00 Phase II 2 countries
Intra-operative evaluation of a novel FLUorescENt C-nnEt tracer in penile and tongue cancer Recruiting

2024-518046-25-00 Phase II 1 country AC-ALA-GLY-SER-CYS(1)-TYR-CYS(2)-SER-GLY-PRO-PRO-ARG-PHE-GLU-CYS(2)-TRP-CYS(1)-T…
Neoadjuvant treatment in rectal cancer with radiotherapy followed by atezolizumab and bevacizumab Recruiting

2024-517119-59-00 Phase II 1 country ATEZOLIZUMAB; BEVACIZUMAB
Pre-operative phase II trial for breast cancer with nivolumab in combination with novel IO (BELLINI trial) Recruiting

2024-515080-54-00 Phase II 1 country DOXORUBICIN HYDROCHLORIDE; NIVOLUMAB; PACLITAXEL; RELATLIMAB
Pre-operative capecitabine, oxaliplatin, docetaxel and atezolizumab in gastric cancer (PANDA) Recruiting

2024-519075-26-00 Phase II 1 country ATEZOLIZUMAB; CAPECITABINE; DOCETAXEL; OXALIPLATIN
Neoadjuvant immune checkpoint inhibition and novel IO combinations in early-stage colon cancer - the NICHE trial Recruiting

2024-513314-35-00 Phase II 1 country ANTI-IL-8 HUMAN MONOCLONAL ANTIBODY; CELECOXIB; IPILIMUMAB; NIVOLUMAB
Substantially improving the cure rate of high-risk BRCA1-like breast cancer patients with personalized therapy (SUBITO) - an international r… Recruiting

2024-516196-32-00 Phase III 2 countries CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; OLAPARIB; PACLITAXEL; …
DRUP trial Recruiting

2023-509152-33-00 Phase II 1 country ABEMACICLIB; ALECTINIB; ALPELISIB; AMIVANTAMAB; ATEZOLIZUMAB; AXITINIB; BEVACIZU…
Anti-PD-1 re-challenge after immune priming by ipilimumab and immune boosting by radiotherapy in advanced NSCLC. Ended

2022-500713-79-00 Phase II/III 1 country CEMIPLIMAB; IPILIMUMAB
Pembrolizumab for locally advanced, irresectable, non-metastatic dMMR colorectal cancers. The PUMA study. Ended

2023-509707-32-00 Phase II 1 country PEMBROLIZUMAB
Body surface area-based vs concentration-based dosing of cisplatin for hyperthermic intraperitoneal chemotherapy (HIPEC) in women with advan… Ended

2024-514711-99-00 Phase II/III 1 country CISPLATIN
A phase 2 study to investigate the effectiveness of combination immunotherapy followed by chemoradiation of the tumor in patients with bladd… Ended

2024-512211-41-00 Phase I/II 1 country
Prospective, randomized, neoadjuvant phase II study with combination immuno-oncology in primary clear cell renal cell cancer at risk for rec… Ended

2024-515514-40-00 Phase II 1 country IPILIMUMAB; NIVOLUMAB
NADINA Ended

2024-513519-28-00 Phase III 4 countries IPILIMUMAB; NIVOLUMAB
PEMbrolizumab Plus Lenvatinib In Second Line And Third Line Malignant Pleural MEsotheLiomA Patients: A Single Arm Phase II Study (PEMMELA). Ended

2024-516618-39-00 Phase II 1 country LENVATINIB; PEMBROLIZUMAB
Hepatic arterial infusion PUMP chemotherapy combined with systemIc chemoTherapy for potentially resectable colorectal liver metastases. - Th… Ended

2024-515525-28-00 Phase II/III 1 country FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN HYDROCHLORIDE TRIHYDRATE; OX…
Immune induction strategies to improve response to immune checkpoint blockade in triple negative breast cancer (TNBC) patients: the TONIC-2 … Ended

2024-513217-12-00 Phase II 1 country CISPLATIN; NIVOLUMAB
Phase III randomized clinical trial for stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or withou… Ended

2023-509049-11-00 Phase III 7 countries BEVACIZUMAB; CARBOPLATIN; CISPLATIN; PACLITAXEL
CRITICS-II Ended

2023-503248-15-00 Phase II 1 country
Treatment of peritoneal dissemination in stomach cancer patients with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy; P… Ended

2023-510159-53-01 Phase II 4 countries DOCETAXEL; OXALIPLATIN
Adaptive phase II randomized non-comparative trial of nivolumab after induction treatment in triple-negative breast cancer (TNBC) patients: … Ended

2025-520487-18-00 Phase II 1 country NIVOLUMAB
PUMP-IT RCT: Hepatic arterial infusion PUMP chemotherapy combined with systemic therapy versus systemic therapy alone as Induction Therapy f… Halted

2023-506194-35-00 Phase III 1 country FLOXURIDINE
LB−100 and azenosertib in metastatic colorectal cancer patients Suspended

2024-511227-33-00 Phase I (Other) 1 country 3-(4-METHYLPIPERAZINE-1-CARBONYL)-7-OXABICLO[2.2.1]HEPTANE-2-CARBOXYLIC ACID; AZ…

Showing 25–48 of 50 trials

← All sponsors A–Z